All In Biotech

Free tool

FAERS Monitor: Jakafi Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217180 or its brand name (Jakafi Xr, Ruxolitinib Phosphate). Reports on generic versions are filed under their own applications.

Reports

10,697

Serious

10,364

97% of reports

Hospitalization

4,097

Death reported

2,687

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,418
  • drug ineffective1,035
  • death787
  • product use in unapproved indication781
  • anaemia738
  • pyrexia597
  • pneumonia578
  • thrombocytopenia562
  • platelet count decreased532
  • haemoglobin decreased511
  • febrile neutropenia458
  • splenomegaly446
  • fatigue404
  • diarrhoea403
  • asthenia375

Reports by year received

View as table
YearReports
201211
201314
201422
201553
2016103
2017209
2018299
2019333
2020528
20211,104
20221,650
20231,844
20241,599
20251,653
20261,275

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,462 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
splenomegalySignal44677.770.932,443
febrile neutropeniaSignal45813.712.55,342
thrombocytopeniaSignal5629.99.24,504
platelet count decreasedSignal5329.99.14,226
haemoglobin decreasedSignal5119.89.04,043
anaemiaSignal7387.67.14,270
product use in unapproved indicationSignal7816.25.83,440
pneumoniaSignal5783.53.21,052
pyrexiaSignal5973.43.11,022
off label useSignal1,4183.23.02,216
asthenia3752.01.8179
death7871.81.7289
drug ineffective1,0351.51.5211
diarrhoea4031.21.117
fatigue4041.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.